drugset

drugset / Trial / NCT01244607

NI-0801 in Allergic Contact Dermatitis

NCT01244607 ↗

Phase 1 Completed 22 enrolled Light Chain Bioscience - Novimmune SA

Randomized

Summary

The purpose of the study is to assess the effect of a single dose of NI-0801 on the severity of nickel-induced allergic contact dermatitis.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NI-0801	Monoclonal antibody	—	Intravenous

Indications